Altimmune Surges on Successful Phase 2b Trial of Pemvidutide

Altimmune shares are trading higher after the company announced positive results from the IMPACT Phase 2b trial, showing significant improvements in non-invasive markers of liver fibrosis in MASH patients and favorable tolerability, paving the way for a Phase 3 trial.